5s in the 2.5mg group.
PT can be predicted by a formula including simple clinical parameters in patients receiving the standard dose of apixaban. This simple predictive formula may help to stratify bleeding and thrombosis risks in patients treated with apixaban.
PT can be predicted by a formula including simple clinical parameters in patients receiving the standard dose of apixaban. This simple predictive formula may help to stratify bleeding and thrombosis risks in patients treated with apixaban.The coarse F waves on the 12-lead surface electrocardiogram (ECG) in patients with atrial fibrillation (AF) are known as atrial viability and contractility indicator. Our aim in this study was to investigate the effect of coarse F wave on thromboembolism in patients with permanent AF.
In our study, 328 patients with permanent AF were included. Routine laboratory, echocardiographic and electrocardiographic parameters were examined. Cerebrovascular event (CVE) or acute artery occlusion was considered a thromboembolic event.
In our study, 46 (14.0%) of the patients were found to have thromboembolic events and 282 (86%) of them were found without thromboembolic events. In the group with thromboembolic event, the number of patients with hypertension (HT) (&lt;.001) and history of coronary artery disease (=.003) and elderly patients (&lt;.001) was significantly higher and warfarin use was significantly lower (=.025). In the group of patients without thromboembolic events, the number of patients with a coarse F wave in surface ECG was significantly lower (=.001). Age (OR 1.105, 95% CI 1.066-1.145, &lt;.001), HT (OR 2.831, 95% CI 1.266-6.331, =.011), and coarse F wave (OR 0.290, 95% CI 0.126- 0.670, =.004) were determined as independent variables for thromboembolic events.
Coarse F wave in 12-lead surface ECG in patients with permanent AF may be associated with good prognosis.
Coarse F wave in 12-lead surface ECG in patients with permanent AF may be associated with good prognosis.This study aims to research the clinical features of atrial thrombi in patients with nonvalvular atrial fibrillation (AF).
This study included 191 patients of AF who had atrial thrombi. One hundred and twenty-eight of them were assigned into nonventricular cardiomyopathy group (non-VCM), and the remaining 63 into ventricular cardiomyopathy group (VCM). After atrial thrombi diagnosed, all patients had taken oral anticoagulant therapy. The resolution rates of thrombi within 12months were compared between the two groups, as well as the locations of thrombi.
Of all 191 patients, 161 had thrombi only detected in left atrial appendage (LAA), 20 in both left atrium (LA) and LAA, six in LA only, and four in right atrium only. More patients had thrombi out of LAA in the VCM group than in the non-VCM group (30.2% vs 8.6%, &lt;.001). After propensity score matching, the atrial thrombi were resolved faster in the non-VCM group than in the VCM group (mean time length 22±2weeks vs 30±3weeks, =.038), and the resolution rate within 12months was higher in the non-VCM group than in the VCM group (88.7% vs 61.4%, Log-rank, =.038). In Cox proportional hazards model, absence of ventricular cardiomyopathy was an independent predictor for the resolution of atrial thrombus (hazard ratio 1.76; =.035).
The patients of atrial fibrillation with ventricular cardiomyopathies have higher incidence of thrombosis in the body of left atrium or right atrium. And the resolution rate was lower in these patients.
The patients of atrial fibrillation with ventricular cardiomyopathies have higher incidence of thrombosis in the body of left atrium or right atrium. And the resolution rate was lower in these patients.Inflammation has been implicated in the initiation and perpetuation of non-valvular atrial fibrillation (AF). However, there is a lack of similar data on AF in rheumatic heart disease (RHD). The objective of this study was to analyze the association of inflammation as measured by serum inflammatory biomarkers with AF in rheumatic mitral stenosis (Rh-MS).
A comparative cross-sectional analytical study was conducted on 181 Rh-MS patients in normal sinus rhythm (NSR; n=69), subclinical transient AF (SCAF; detected by 24-hours Holter monitoring; n=30) and chronic AF (n=82). Serum hs-CRP, IL-6, and sCD-40L were assessed using ELISA immunoassay and compared in all groups of Rh-MS with or without AF.
We found significantly higher serum hs-CRP and sCD-40L levels in the overall AF (Chronic AF+SCAF) group (4.5±3.4 vs 2.3±2.9mg/L, &lt;.01; 6.4±4.8 vs 3.1±3.4ng/mL, &lt;.01) and chronic AF subgroup (4.9±3.4 vs 2.3±2.9mg/L, &lt;.01; 6.9±5.1 vs 3.1±3.4ng/mL, &lt;.01) compared to patients with sinus rhythm. https://www.selleckchem.com/products/pri-724.html There was a statistically significant graded increase of serum IL-6 level from the NSR to the SCAF (6.8±3.9 vs 4.0±2.2pg/mL, =.03), and chronic AF subgroups (9.3±6.5 vs 4.0±2.2pg/mL, &lt;.01; vs 9.3±6.5 vs 6.8±3.9, =.05) of atrial fibrillation.
Elevated levels of serum hs-CRP, IL-6, and sCD-40L were strongly associated with overall AF and also with SCAF and chronic AF in Rh-MS patients indicating a potential role of inflammation in the pathophysiology of rheumatic AF.
Elevated levels of serum hs-CRP, IL-6, and sCD-40L were strongly associated with overall AF and also with SCAF and chronic AF in Rh-MS patients indicating a potential role of inflammation in the pathophysiology of rheumatic AF.A scoring system to determine indications for catheter ablation (CA) in atrial fibrillation (AF) is desired.
Among 2898 consecutive patients with AF, CA was performed in 938 (32.4%). A new HEAL-AF score has been developed by six variables, all of which were independently associated with CA by multivariate analysis and for each 1 point was assigned heart failure???NYHA II, elderly patients (age??75years), asymptomatic AF, long-standing persistent AF, atrial dilation (left atrial diameter?50mm), and female sex. Low HEAL-AF score was associated with high incidence of CA performance (52.0% for 0, 36.5% for 1, 15.1% for 2, and 5.6% for?3) and the predictive capability of this score by AUC of ROC curve was 0.720 (95% CI 0.701-0.739, &lt;.001). The rates of freedom from AF/AT recurrence were 73.2% in HEAL-AF score 0, 71.0% in 1, 60.0% in 2, and 50.0% in?3 (log-rank test, =.004). HEAL-AF score 2 and?3 were significantly associated with recurrence of atrial tachyarrhythmia as compared with HEAL-AF 0 (HR 1.755, =.